ABSTRACT Up to about the early 1980s it was perhaps still possible to summarize in a review of a moderate length the development of the medicinal applications of chelation chemistry and the exploitation of such chemistry in regulating the metal ion concentrations in the body. However, in the last few years there has a great surge in the development of chelation chemistry and its usage in medicine and related areas of life sciences research. It is no longer the case that such a review primarily concentrates upon the use of chelating agents in removing toxic metals from the body but it must now cover the use of chelating agents in the imaging procedures nuclear medicine and magnetic resonance imaging (MRI), the use of chelating agents in unravelling the biochemistry of reactive oxidative species (ROS) and the control and measurement of intracellular calcium ions. It is in the recent applications that there have been the greatest developments over the last ten years.
INTRODUCTION: THE CONTINUING DEVELOPMENT OF CHELATION CHEMISTRY IN MEDICINE
The essentiality of several trace metals for our good health is well recognized but in more recent years many metal compounds have also been recognized as environmental and work-place carcinogens (1, 2 and reviews therein). These observations, the use of chelated metal ions in non-invasive diagnostic medical procedures, such as nuclear medicine and MRI, the need to control the levels of toxic metal ions in the body and the search for inorganic drugs other than cisplatin and auranofin have led to extensive developments in chelation chemistry. Although inorganic drugs are always going to be minor components of a pharmacopoeia, it is possible that they might become important therapies for some significant diseases such as diabetes which in western industrial nations has an incidence of 1 in 300 (3). Although insulin replacement is the easiest method of controlling chronic diabetes the only satisfactory route of administration is by injection and this has prompted the search for orally deliverable therapies. Currently much interest has been shown in the inorganic biochemistry of vanadium as in some forms it is an orally active insulin mimetic (4). Although vanadate is active, its uptake from the gastrointestinal tract is low but vanadyl bis-maltolato is orally active and is a powerful insulin mimetic (5). The recently reported metabolic problems ascribed to vanadium in Thais dwelling in regions with vanadium-rich soils (6) should be studied in depth before the launch of vanadium-containing pharmaceuticals.
It is clear from studying the literature on inorganic biochemistry in its widest forms, from the speciation of metal ions to investigations of the clearance of toxic metal ions from the body, that many novel approaches have been used to modify the behaviour of the biological response to metal ions. Although low molecular weight chelating agents have been the major mechanism for modifying biological response to metal ions, other procedures which exploit metalloproteins are almost certainly going to become feasible as genetic engineering develops. Already of note has been the production of an antibody which bears a functioning metallothionein which can be loaded with cationic 99mTc
and then targeted to cells (7) . The recent considerations about metallothionein and cancer (8) might lead to further investigations of such genetic engineering.
The reasons for giving serious consideration to the contribution of inorganic elements to mammalian biochemistry continue to grow and it is clearly unwise to assume there is a full understanding of mammalian biochemistry because of the use metabolic pathways as vanity boards in laboratories and offices. The continuing development of analytical instrumentation is likely to lead to the identification of more essential trace elements or the concentration of elements in diseased tissue.
For instance, by using particle induced X-ray emission spectroscopy strontium was identified in the granulocytes of patients with rheumatoid arthritis and shown to fall from 5.1 pg/g dry weight to 1.7 pg/g over a three month course of treatment with anti-inflammatory drugs (9) . The extent to which chelating agents have continued to be the subject of study in biochemistry and medicine can be judged from Table 1 which was compiled from an on-line search of Med/ine using the search terms chelat* and the names of various chelating agents. Unfortunately because of the way the files on the Medline database are currently constructed it is impossible to summarize the data for a sequence of, say five years, by other than an much more expensive search. By using some additional terms it has also been to obtain some idea of the number of publications in which D-penicillamine was likely to have been discussed primarily in the treatment of rheumatoid arthritis. From the number of hits for 1985-89 and from 1990 to July 1993 it is clear that research applications of chelating agents in medicine and the relevant life sciences shows no sign of declining but is actually increasing. By the mid-1960s the initial use of chelating agents in medicine as almost a panacea had practically stopped, so it might be presumed that the hits for the years from 1966 onwards primarily reflect accounts of their use for chelation of metal ions in medicine and the relevant life sciences. No doubt many of these uses in life sciences reflect the development of inorganic biochemistry. Even the N-CH2COOH moiety of the polyaminopolycarboxylic acids (PAPCs) and 2,2'-bipyridyl are to be found in nature in pyridine-2,6-dicarboxylic acid and bipyridyl-containing caerlomycin (13). In a recent extensive review, well worth detailed study, Michael and Pattenden have taken a critical look at potential metal ion chelation by marine metabolites (14) . In man regulation of the concentration of metal ions is achieved primarily by uptake by macromolecules such as transferrin, ferritin, metallothionein, caeruplasmin and, rather weakly, by serum albumin. Regulation of metal ions by low molecular weight chemicals appears to be primarily by citrate and amino acids. The extent to which an interaction of adrenaline, the possessor of the o-catechol moiety, with copper(ll) and iron(l I) has any significance in our wellbeing, or perhaps lack of it, is still to be demonstrated as catecholamines are prone to autooxidation in the presence of transition metal ions. The occurrence of 3,4-dihyroxyphenylalanine in the primary sequence of some proteins has been noted (15) but the participation of this moiety in metal-binding has yet to be determined. The occurrence of vanilmandelic acid in neuroblastoma has been noted (16) as has the occurrence of a siderophoregrowth factor in virally transformed cells (17) . A role for higher aliphatic 2,4-diketones, a ubiquitous lipid family with chelating properties, is still being sought, although it is recognized that they exhibit anti-allergic and antihistamine properties (18).
METAL IONS IN CELLS
As Sorenson (19) covering these uses has been reviewed (10). had low toxicity and were effective. An effective blocking of enterohepatic recirculation of methyl-mercury(ll) in rural-dwelling Iraqis, who consumed grain which had been treated with a mercury-based fungicide, was achieved by using a thiol-containing macromolecule.
Chelation-based procedures for removing toxic metal ions from bone, and also directing the uptake of gamma-ray emitting radionuclides to bone, have also been sought. Whereas procedures for selective direction of some chelating agents to soft tissues have been relatively successful, and are the subject of further discussion below, the success in directing chelating agents to bone is perhaps not quite so evident. As a fuller summary of the interaction of chelating agents, and chelated radionuclides, with bone is given elsewhere (36) only a brief outline is given here. Uptake of N-acetate-type chelating agents by bone appears to be low, 0.2% uptake, and is restricted to some iminodiacetates which form calcium chelates with stability constants of log K 5. Presumably the uptake of xylenol orange and calcein blue by bone is determined by the N,N-iminodiacetate moieties they contain.
The affinity of tetracycline for calcified tissues presumably arises from keto-enol group generated by the 11,12-diketone group (37). A highly effective uptake into bone of gamma-ray emitting radionuclides, such as 99mTc, by using bis-phosphonates has become the basis of extensively exploited procedures for the detection of excessive bone growth due to tumours (38) and Paget's disease (39). More recently some N-substituted phosphonates derived from dimethylamino-dicyclopentadiene and dimethylaminonorborane have been evaluated and might also become important vehicles for targeting radionuclides to bone (40).
To achieve a significant manageability of the use of chelation agents in decorporation therapy, their usage has been summarized in Table 3 . With the exception of HPO, the hydroxypyridones (Fig. 5) , these chelating agents are listed in the pharmacopoeia of many nations. The extent to which toxic metal ions have been removed from the human body and thus been life-saving is not always easy to assess. In spite of the reservations in the USA of the use of prophylactic chelation (41-43), from laboratory studies on animals and the many cases of clinical usage, the evidence is substantial that chelation therapy to combat the intake of toxic metal ions by humans is clearly beneficial. Perhaps one of the most demonstrative studies of the benefits of chelation therapy is the marked reduction of the incidence of bone sarcomas in mice, the recipients of ZnDTPA chelation therapy to counter the radiobiological consequences of intravenously injected 239pu(IV) citrate (44). In humans the benefits of DFOA therapy in relieving the painful symptoms of aluminium uptake into bone have been clearly demonstrated (45) . DFOA has also clearly been of value for combating aluminium-induced dialysis encephalopathy (46, 47) . Recently it has been reported that intramuscular injections of DFOA halted the decline in daily the living skills of patients with Alzheimer's disease (48). However, the role of aluminium in the aetiology of this disease continues to be controversial (49, 50 Jones (12) has summarized his extensive investigations of the structure-activity relationships of a series of dithiocarbamic acids prepared to counter incorporated cadmium (Table 4 and Fig. 8 ). As can be seen from In the last few years the developments in synthetic organic chemistry of the EDTA-and DTPA-like molecules has become extensive and are briefly summarized in Table 5 . There have also been similar developments in the chemistry of N-substituted 1,4,7,10-tetrazacycloalkanes (Table 6 ). The principal impetus in the development of these chelate-bearing MoAbs has been in nuclear medicine 
NUCLEAR MEDICINE
Nuclear medicine has been one of the reat boons of the nuclear age. The principal radionuclide 99 used in imaging radiopharmaceuticals isU9mTc, t 6.02 h, the decay product of Mo, t, 66 h, which is retained as molybdate on an alumina column. After elution as the pertechnate ion, TcO4, in sterile saline, various reducing agents are used in the presence of a chelating agent, although occasionally the ligand is not a chelating agent, to yield radiopharmaceuticals containing Tc(V), Tc(VI), Tc(lll) or Tc(I)o By selection of suitable ligands it is possible direct the radionuclide to various organs or diseased tissue and, also, ensure a rapid high uptake of the radionuclide into the target tissue into contrast to a continuing circulation in blood. The contribution of slight structural variations of a series of acetanilidoiminodiacetates upon the distribution of ssrnTc in mice has been summarized (95).
Also of note is an extensive study of the species-dependent distribution of 99mTc in various oxidation states when complexed by 1,2-bisdimethylphosphinoethane (96). Further discussion of the use of chelating agents in nuclear medicine appears elsewhere (10). A detailed account of the coordination 99m chemistry of radiopharmaceuticals has recently been issued (97). Although Tc-containing radiopharmaceuticals are the major chemicals used in nuclear imaging of the body other chelated 67 111 radionuclides (principally Ga(lll) and In (111) 
1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane the diversity of the ligands which might be used to form imaging radiopharmaceuticals and radiotherapies. In the last few years nuclear medicine has expanded further by using more selective procedures to target radionuclides to tissues by using chelating agents chemically immobilized on monoclonal antibodies. Although some of these MCAs have been used to improve targeting of nuclear imaging, they have mainly been developed for radiotherapy. Torchilin and Kilbanov (98) 
